Gossamer Bio appoints Greg Ciongoli to board, Audit Committee

Gossamer Bio, Inc.

Ciongoli, Class III director effective Sept 16, 2026, term to 2027 annual meeting; joins Audit Committee.
Founder/managing partner of Adiumentum Capital (since 2024); ex-Baupost Group partner; also on REGENXBIO, Zymeworks, Atara boards.
He participated in Aug 2026 PIPE: pre-funded warrants for ~22,337 common (initial), ~111,687 (second closing), ~66,845 (FDA approval) post-approval.
Annual cash retainers: $40,000 board, $7,500 audit; standard equity award amount set at future board discretion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.